N
KLRS

Nuveen’s Kalaris Therapeutics KLRS Stock Holding History

Nuveen’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,092
Closed -$351K – 3368
2023
Q3 		$351K Sell
7,092
-46
-0.6% -$3.13K ﹤0.01% 2941
2023
Q2 		$558K Buy
7,138
+601
+9% +$57.1K ﹤0.01% 2888
2023
Q1 		$592K Sell
6,537
-505
-7% -$64.3K ﹤0.01% 2766
2022
Q4 		$831K Sell
7,042
-638
-8% -$108K ﹤0.01% 2754
2022
Q3 		$1.39M Sell
7,680
-62
-0.8% -$9.66K ﹤0.01% 2577
2022
Q2 		$694K Buy
7,742
+4,228
+120% +$443K ﹤0.01% 2932
2022
Q1 		$613K Buy
3,514
+26
+0.7% +$5.19K ﹤0.01% 2955
2021
Q4 		$1.15M Sell
3,488
-286
-8% -$133K ﹤0.01% 2813
2021
Q3 		$2.08M Sell
3,774
-83
-2% -$38.4K ﹤0.01% 2657
2021
Q2 		$1.75M Sell
3,857
-479
-11% -$247K ﹤0.01% 2775
2021
Q1 		$2.33M Buy
4,336
+883
+26% +$742K ﹤0.01% 2544
2020
Q4 		$3.05M Buy
3,453
+171
+5% +$132K ﹤0.01% 2298
2020
Q3 		$2.08M Buy
+3,282
New +$2.24M ﹤0.01% 2365

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Nuveen's KLRS Position: Q4 2023 in Review

Nuveen sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 7,092 shares — an estimated $351K sold.

Nuveen first reported a position in KLRS in Q3 2020 and held it in 13 quarters. The position peaked at $3.05M in Q4 2020. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Nuveen reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Nuveen sold 7,092 Kalaris Therapeutics shares in Q4 2023, an estimated $351K.
  • Nuveen first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 13 quarters.
  • Nuveen's Kalaris Therapeutics position peaked at $3.05M in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Nuveen's 13F filing for Q4 2023, filed 14 Feb 2024.